Contraindications and Cautions for Tramadol Use

Absolute Contraindications

• Tramadol is absolutely contraindicated in patients with acute intoxication by alcohol, hypnotics, narcotics, centrally acting analgesics, or psychotropic drugs. 1
• Tramadol is absolutely contraindicated in patients with acute intoxication by other opioids. 2

Strong Drug‑Interaction Contraindications

• Co‑administration of tramadol with monoamine‑oxidase inhibitors (MAOIs) markedly increases the risk of seizures and serotonin syndrome; animal studies have demonstrated increased mortality with the combined use. 3

Seizure‑Related Risks

• Tramadol should be avoided or used only with extreme caution in patients with epilepsy, a prior history of seizures, or recognized seizure‑risk factors such as head trauma, metabolic disturbances, alcohol or drug withdrawal, and central nervous system infections. 3
• Concomitant use of neuroleptic agents, which lower the seizure threshold, further heightens seizure risk when combined with tramadol. 1

Respiratory‑Depression Risks

• Tramadol should be avoided or used with extreme caution in patients who have compromised respiratory function. 4

Renal‑Impairment Considerations

• In patients with renal impairment, tramadol should be avoided unless no alternative analgesics are available; alternative opioids such as methadone, fentanyl, oxycodone, or hydromorphone are preferred. 1

Pharmacogenomic Factors (CYP2D6)

• Individuals who are CYP2D6 poor metabolizers—more prevalent among Asian populations—experience reduced or absent analgesic benefit from tramadol; this is not an absolute contraindication but limits efficacy. 5
• Tramadol is a pro‑drug that requires CYP2D6‑mediated metabolism to produce its analgesic effect. 2

CYP‑Mediated Drug Interactions

• Co‑administration of strong CYP2D6 inhibitors diminishes tramadol’s analgesic effect and should be avoided. 1
• Drugs that compete for CYP2D6 metabolism may similarly reduce tramadol’s efficacy and warrant extreme caution. 1

Dose‑Titration and Neurotoxicity Limitations

• Tramadol has a low threshold for neurotoxicity, limiting the ability to titrate doses safely. 2

Comparative Analgesic Efficacy

• Evidence of very low certainty suggests that tramadol may be less effective than morphine for managing moderate cancer‑related pain. 5

Safety and Efficacy Guidelines for the Tramadol‑Promethazine Combination

Pharmacologic Risks

• Serotonin‑Syndrome Risk: Tramadol’s serotonin‑reuptake inhibition warrants caution or avoidance when combined with other serotonergic agents because of the potential for serotonin syndrome. National Comprehensive Cancer Network (NCCN) guideline, 2025 6
• Increased CNS Toxicity: Although promethazine is not primarily serotonergic, co‑administration with tramadol adds to overall central‑nervous‑system toxicity. NCCN guideline, 2025 6
• Limited Analgesic Potency: Tramadol provides only about one‑tenth the analgesic potency of morphine and shows limited effectiveness for moderate cancer‑related pain. NCCN guideline, 2025 6

Dosing Recommendations

• Maximum Daily Dose (Adults with Normal Hepatic/Renal Function): Do not exceed 400 mg/day for immediate‑release tramadol or 300 mg/day for extended‑release formulations. NCCN guideline, 2025 6
• Dose Reduction for Older Adults and Organ Impairment: In patients aged ≥ 75 years or those with hepatic or renal dysfunction, tramadol doses must be lowered to mitigate seizure risk. NCCN guideline, 2025 6

Evidence‑Based Use and Contraindications

• Routine Pain Management Not Supported: The tramadol‑promethazine combination lacks evidence‑based support for routine analgesia and should be avoided outside specific peri‑operative or obstetric scenarios. NCCN guideline, 2025 6

Preferred Alternative Approaches

• Single‑Agent Opioid Therapy: For moderate pain requiring opioid treatment, the NCCN recommends using a single‑agent opioid such as morphine, oxycodone, or hydromorphone without adding promethazine unless a clear anti‑emetic indication exists. NCCN guideline, 2025 6

Strength of evidence: The NCCN guideline does not specify a formal evidence grade for these statements; they are based on expert consensus and available clinical data.